AI Summary
The article discusses the use of circulating-tumor DNA (ctDNA)-based molecular residual disease (MRD) detection in patients with colorectal liver metastases (CLM). The study aims to explore the survival benefit of adjuvant chemotherapy (ACT) in this patient population after surgical resection. This research could potentially provide valuable insights into risk-stratification and treatment options for individuals with CLM.
The prognostic role of circulating-tumor DNA (ctDNA)-based molecular residual disease (MRD) detection and its utility for postsurgical risk-stratification has been reported in colorectal cancer. In this study, we explored the use of ctDNA-based MRD detection in patients with colorectal liver metastases (CLM), for whom the survival benefit of adjuvant chemotherapy (ACT) after surgical resection remains unclear.